Review summarizes fenofibrate, metformin, and MSC modulation in Primary Sjögren disease management

This publication is a review focusing on the management of Primary Sjögren disease. The authors synthesize evidence regarding interventions that modulate the proliferation, activation, and functional balance of regulatory T cells (Tregs), mesenchymal stem cells (MSCs), fenofibrate, and metformin. The scope encompasses mechanisms related to inflammatory responses, immune activation, tissue pathological damage, saliva secretion, and tear secretion.

Key findings indicate that fenofibrate and metformin, alongside MSCs, may promote Treg proliferation and function significantly. The review suggests these interventions could improve the Th17 to Treg immune balance effectively. Additionally, the authors report reduced inflammatory responses and downregulated immune activation levels. Tissue pathological damage is described as alleviated, while saliva and tear secretion are noted to increase substantially.

Despite these mechanistic observations, the review does not report specific sample sizes, follow-up durations, or statistical values such as p-values or confidence intervals. Safety data, including adverse events, serious adverse events, and discontinuations, are also not reported in the text. The authors acknowledge the lack of specific clinical trial data within this synthesis of evidence.

Practice relevance is framed as providing a theoretical basis for the development of novel treatment approaches for Primary Sjögren disease. Clinicians should recognize that these findings represent a theoretical framework rather than established clinical evidence. Further research is required to validate these mechanisms in controlled settings before clinical application occurs.